mezigdomide
Sponsor Bristol Myers Squibb CO · listed as BMY
mezigdomide is a drug asset sponsored by Bristol Myers Squibb CO, listed as BMY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jan 10, 2027 (day precision, medium confidence), tied to trial NCT05519085. That trial is in Phase 3 and currently recruiting, studying Relapsed or Refractory Multiple Myeloma. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for mezigdomide in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05552976 | Phase 3 | Active, not recruiting | 2026-09-28 | Experimental | Bristol-Myers Squibb | Relapsed or Refractory Multiple Myeloma |
| NCT05519085 catalyst | Phase 3 | Recruiting | 2027-01-10 | Experimental | Celgene | Relapsed or Refractory Multiple Myeloma |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More BMY catalysts